KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Equity Ratio (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Equity Ratio data on record, last reported at 0.01 in Q4 2025.

  • For Q4 2025, Equity Ratio fell 98.3% year-over-year to 0.01; the TTM value through Dec 2025 reached 0.01, down 98.3%, while the annual FY2025 figure was 0.01, 98.3% down from the prior year.
  • Equity Ratio reached 0.01 in Q4 2025 per PACB's latest filing, down from 0.04 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.41 in Q3 2021 and bottomed at 0.01 in Q4 2025.
  • Average Equity Ratio over 5 years is 0.29, with a median of 0.35 recorded in 2022.
  • Peak YoY movement for Equity Ratio: skyrocketed 75.33% in 2022, then tumbled 98.3% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.39 in 2021, then dropped by 19.17% to 0.32 in 2022, then grew by 26.09% to 0.4 in 2023, then increased by 0.06% to 0.4 in 2024, then crashed by 98.3% to 0.01 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.01 in Q4 2025, 0.04 in Q3 2025, and 0.07 in Q2 2025.